期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
二肽酶Ⅳ抑制剂Ondero
1
《药学进展》 CAS 2009年第1期44-46,共3页
关键词 Ondero 二肽酶ⅳ抑制剂 糖尿病
下载PDF
2型糖尿病药物治疗新进展——肠促胰岛素激素类似物及二肽酶-Ⅳ抑制剂 被引量:1
2
作者 张茜 肖新华 《国际内科双语杂志(中英文)》 2006年第10期58-61,共4页
早在20世纪60年代末期,Perley等发现,即使在相同的血糖浓度下,口服葡萄糖后刺激胰腺8细胞分泌的胰岛素多于静脉给予葡萄糖后分泌的胰岛素。这提示肠道可能释放对胰岛素分泌具有调节作用的因子。直到近年才发现并命名该因子,称之为... 早在20世纪60年代末期,Perley等发现,即使在相同的血糖浓度下,口服葡萄糖后刺激胰腺8细胞分泌的胰岛素多于静脉给予葡萄糖后分泌的胰岛素。这提示肠道可能释放对胰岛素分泌具有调节作用的因子。直到近年才发现并命名该因子,称之为肠促胰岛素激素(incretin)。它包括葡萄糖依赖性促胰岛素多肽(glucose -dependent insulinotropic peptide,GIP)和胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)。 展开更多
关键词 肠促胰岛素激素类似物 二肽酶-抑制 2型糖尿病
下载PDF
保护胰岛功能及促进胰岛再生的临床治疗进展 被引量:2
3
作者 唐伟 段宇 刘超 《国际内科学杂志》 CAS 2009年第11期643-647,651,共6页
胰岛功能受损是1型糖尿病的始动因素,也是2型糖尿病发病的中心环节。随着病程的进展,多种机制参与导致β细胞的功能进行性下降。如能够在早期及时发现β细胞的功能减退,并通过给予胰岛素强化治疗、钾通道开放剂、噻唑烷二酮类、血管紧... 胰岛功能受损是1型糖尿病的始动因素,也是2型糖尿病发病的中心环节。随着病程的进展,多种机制参与导致β细胞的功能进行性下降。如能够在早期及时发现β细胞的功能减退,并通过给予胰岛素强化治疗、钾通道开放剂、噻唑烷二酮类、血管紧张素转化酶抑制剂/血管紧张素受体Ⅰ拮抗剂、肠促胰岛素及类似物、二肽酶-Ⅳ抑制剂等药物及时有效地治疗以保护胰岛β细胞功能、促进胰岛再生,对糖尿病的防治具有重要意义。 展开更多
关键词 2型糖尿病 Β细胞功能 胰岛再生 肠促胰岛素 二肽酶-抑制
下载PDF
Efficacy and safety of saxagliptin in patients with type 2 diabetes mellitus:a meta-analysis of randomized controlled trials 被引量:2
4
作者 姚莉 范芳芳 +2 位作者 胡兰 赵生俊 郑丽丽 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2016年第2期128-139,共12页
As a new oral hypoglycemic agent, saxagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. However, it remains inconclusive whether saxagliptin is associated with increased risk of adverse even... As a new oral hypoglycemic agent, saxagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. However, it remains inconclusive whether saxagliptin is associated with increased risk of adverse events (AE) and efficacy as add-on treatment. Therefore, we performed an up-to-date meta-analysis to compare the efficacy and safety of saxagliptin with placebo and other oral hypoglycemic agents in adult patients with type 2 diabetes mellitus (T2DM). Randomized clinical trials (RCTs) comparing saxagliptin with comparators were retrieved by selecting articles from Pubmed, Embase, Cochrane Library and Clinical Trials Registry Platform up to Oct. 2013. Weighted mean difference (WMD) was used to analyze the effect of hypoglycemic agents on HbAlc, weight and fasting plasma glucose (FPG). While the patients who achieved HbAlc〈7.0% and had AE were analyzed as relative risks (RR). A total of 18 articles from 16 RCTs and one clinic trial from the WHO International Clinical Trials Registry Platform met the included criterion. Clinically significant decrease from baseline HbAlc compared with placebo was certified for 2.5 mg/day saxagliptin (WMD = -0.45%, 95% CI, -0.48% to -0.42%) and 5 mg/d saxagliptin (WMD = -0.52%, 95% CI, -0.60% to -0.44%). Saxagliptin as add-on therapy was superior to thiazolidinediones, up-titrated glyburide, up-titrated metformin or metformin monotherapy in achieving HbA1c〈7.0%. Treatment with saxagliptin had negligible effect on weight, and it was considered weight neutral. Saxagliptin treatment did not increase the risk of hypoglycemia (RR = 1.28, 95% CI 0.72 to 2.27, P = 0.40) and serious adverse experiences (RR = 1.25, 95% CI 0.94 to 1.66, P = 0.13). No statistically significant differences were observed between saxagliptin and comparators in terms of the risk of infections. The present study showed that saxagliptin was effective in improving glycaemic control in T2DM with a low risk of hypoglycaemia and incidence of infections in either monotherapy or add-on treatment. This founding should be further certified by large-sample size and good-designed RCT. 展开更多
关键词 DPP-4 inhibitor SAXAGLIPTIN META-ANALYSIS Type 2 diabetes mellitus Fasting plasma glucose Glycosylated hemoglobin Randomized controlled trial HYPOGLYCAEMIA
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部